解剖病理学の世界市場：現状分析と予測（2022年～2028年）

世界の解剖病理学の市場規模は、2021年から2027年にかけて約6.45%のCAGRで成長すると予想されています。市場の成長を後押しする主な要因には、高齢者人口の増加、がんやその他の関連慢性疾患の高い有病率、政府の厳しい規制、ヘルスケア業界の主要ステークホルダーが、製品やサービスをより持続可能で環境に優しいものにするための採用に注力していることなどが挙げられます。

当レポートでは、世界の解剖病理学市場を調査しており、市場の概要、市場規模や予測、動向、促進要因・抑制要因、製品・サービス別・用途別・エンドユーザー別・地域別の分析、および企業プロファイルなどを提供しています。

目次

第1章 市場イントロダクション

• 市場の定義
• 主な目的
• ステークホルダー
• 制限

第2章 調査手法または前提条件

• 解剖病理学市場の調査プロセス
• 解剖病理学市場の調査手法
• 予測方法

第3章 市場の要約

第4章 エグゼクティブサマリー

第5章 世界の解剖病理学市場へのCOVID-19の影響

第6章 世界の解剖病理学市場の収益、2020年～2028年

第7章 市場洞察：製品・サービス別

• 機器
• 消耗品
• サービス

第8章 市場洞察：用途別

• 病気の診断
• 創薬・開発
• その他

第9章 市場洞察：エンドユーザー別

• 病院
• 研究ラボ
• 診断ラボ
• その他

第10章 市場洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他の北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • オーストラリア
  • その他のアジア太平洋
• その他の地域

第11章 解剖病理学の市場力学

• 市場促進要因
• 市場抑制要因
• 影響分析

第12章 解剖病理学の市場機会

第13章 解剖病理学の市場動向

第14章 政策と規制の枠組み

第15章 需要側と供給側の分析

• 需要側の分析
• 供給側の分析

第16章 バリューチェーン分析

第17章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第18章 企業プロファイル

• F. Hoffman-La Roche Ltd.
• Danaher corporation
• Thermo Fisher Scientific
• BioGenex Laboratories
• Hologic Inc.
• Agilent Technologies
• Becton, Dickinson and Company
• Sakura Finetek USA Inc.
• Merck KGaA
• Bio SB

第19章 免責事項

The global anatomic pathology market is experiencing significant growth due to the increasing geriatric population coupled with rising cancer, stepping growth on the support of extensive use of anatomic pathology for identifying and managing tumors that are growing at an alarming rate. For instance, In May 2021, Hologic received premarket approval (PMA) from the FDA for its ThinPrep GenesisTM processor for cytology processing and specimen transfer for downstream applications. The launch of the ThinPrep Genesis processor shows our continued commitment to improving the testing experience for our laboratory partners and, ultimately, helping them and clinicians deliver accurate results. Thus, the latest approval will boost Hologic's diagnostics solutions offering with the growing focus on technology and increase the accuracy of cervical cancer screening used by laboratories which gives detailed information about patients. Therefore, the market for anatomic pathology is expected to witness a significant CAGR of 6.45% during the forecast period.

The global anatomic pathology market is expected to register a CAGR of around 6.45% from 2021 to 2027. This is mainly due to the high prevalence of cancer and other associated chronic diseases coupled with the growth in the geriatric population and the stringent government regulations coupled with the growing focus of major stakeholders in the healthcare industry to adopt to make products and services more sustainable and eco-friendlier. Major healthcare companies are investing heavily in their products due to the rising prevalence of cancer, with the number of patients with chronic disease rising which includes the growth of cancer cases among the older population. According to National Cancer Institute, The incidence rates for cancer overall climb steadily as age increases, from fewer than 25 cases per 100,000 people in age groups under age 20 to about 350 per 100,000 people among those aged 45-49, to more than 1,000 per 100,000 people in age groups 60 years and older. Thus, increase in the prevalence of cancer, there is increasing usage of advanced pathology equipment such as staining systems, gross imaging, and digital microscopes that are poised to improve anatomic pathological practices to some extent. Furthermore, various factors such as smoking, unhealthy diet, physical inactivity, and advancing age, increase the risk and diagnosis of such diseases. Therefore, the market for anatomic pathology devices is expected to witness significant growth during the forecast period.

F. Hoffman-La Roche Ltd., Danaher Corporation, Thermo Fisher Scientific, BioGenex Laboratories, Hologic, Inc., Agilent Technologies, Becton, Dickinson and Company, Sakura Finetek USA Inc., Merck KGaA, Bio SB are some of the key players in the market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report:

"Amongst Product and Services, services category accounted for the majority share in the market in 2020"

Based on the product and services, the market is categorized into instruments, consumables, and services. The services category accounted for a significant share of the market. This is mainly due to the rising prevalence of critical illnesses that require immediate medical attention. A substantial number of reagents and kits, antibodies, and probes are being marketed for anatomic pathology protocols. The growth of this segment can be attributed to the drive to enhance technical capabilities to offer anatomic pathological instruments with an improved design. For instance, in April 2020, Precisionary Instruments launched a CF-6100 cryostat. This cryostat promotes and supports tissue sectioning in dermatology, histology, and pathology. The continuous development of the new products due to technological advancements that will lead to the production of innovative instruments and procedures is likely to strengthen the market of the segment during the forecast period.

"Amongst Application, disease diagnosis is expected to witness highest CAGR during the forecast period"

Based on the application, the market is categorized into disease diagnosis, drug discovery and development, and others. Among these, disease diagnosis is expected to witness the highest CAGR during the forecast period. This is mainly due to pathology protocols providing an opportunity for researchers to explore disease etiology and associated outcomes. For instance, according to NCBI, Larger laboratories accessioning 20,000 or more specimens per year face a high rate of discrepancies as compared to those receiving less than 20,000 samples. The Rising cases of chronic disease and increasing requirements to address the timely diagnosis of medical conditions are driving the market. However, the rising prevalence of cancer along with the surging geriatric population is the major factor driving the disease diagnosis over the forecast period.

"North America to witness significant growth during the forecast period"

North America is expected to show the highest CAGR growth in the anatomic pathology market. The major contributors to the growth of this market are US and Canada. This is mainly due to the increasing incidence of cancer which causes death in countries like the U.S. and Canada. The growing implementation of digital pathology services with advanced imaging tools also significantly contributed to the considerable growth of the state in the U.S. anatomic pathology market. The Increase in awareness about anatomic pathology, health screening, and the rise in the patient base suffering from cancer in the U.S. is expected to drive the market in the region. As per the American Cancer Society (2021), 1 in 3 people will be diagnosed with cancer in their lifetime. Furthermore, many medical and pharmaceutical companies are headquartered in the region, which is now focusing on research and development and clinical research activity for the treatment of cancer and various developmental strategies adopted by the regional market will drive market growth.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts.

• The report presents a quick review of overall industry performance at one glance.

• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments.

• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry.

• The study comprehensively covers the market across different segments.

• Deep dive regional level analysis of the industry.

Customization Options:

The global anatomic pathology market can further be customized as per the requirement of any other market segment. Besides this, UMI understands that you may have your own business needs, hence feel free to connect with us to get a report that completely suits your requirements.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Anatomic Pathology Market
• 2.2. Research Methodology of the Anatomic Pathology Market
• 2.3. Forecasting Method

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL ANATOMIC PATHOLOGY MARKET COVID-19 IMPACT

6 GLOBAL ANATOMIC PATHOLOGY MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY PRODUCT AND SERVICES

• 7.1. Instruments
• 7.2. Consumables
• 7.3. Services

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Disease Diagnosis
• 8.2. Drug Discovery and Development
• 8.3. Others

9 MARKET INSIGHTS BY END USER

• 9.1. Hospitals
• 9.2. Research Laboratories
• 9.3. Diagnostic Laboratories
• 9.4. Others

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. UK
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Australia
  • 10.3.5. Rest of Asia-Pacific
• 10.4. Rest of World

11 ANATOMIC PATHOLOGY MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 ANATOMIC PATHOLOGY MARKET OPPORTUNITIES

13 ANATOMIC PATHOLOGY MARKET TRENDS

14 POLICY & REGULATORY FRAMEWORK

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porter's Five Forces Analysis

18 COMPANY PROFILED

• 18.1. F. Hoffman-La Roche Ltd.
• 18.2. Danaher corporation
• 18.3. Thermo Fisher Scientific
• 18.4. BioGenex Laboratories
• 18.5. Hologic Inc.
• 18.6. Agilent Technologies
• 18.7. Becton, Dickinson and Company
• 18.8. Sakura Finetek USA Inc.
• 18.9. Merck KGaA
• 18.10. Bio SB

19 DISCLAIMER